Clinical Trial Update: Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating three oral doses of quinagolide over three weeks for ovarian hyperstimulation syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Hyperstimulation Syndrome

Drugs mentioned

• quinagolide (quinagolide)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Ovarian Hyperstimulation Syndrome | Phase 2 | Status: COMPLETED